Eosinophilic esophagitis and comorbid pathology: current state of the problem
https://doi.org/10.31146/1682-8658-ecg-219-11-138-145
Abstract
Eosinophilic esophagitis and asthma are often found as part of comorbid pathology in children and adults, along with other manifestations of atopy. The two diseases share similar pathophysiology due to T-helper type 2 responses, common treatment approaches such as the use of glucocorticosteroids and targeted anti-cytokine biologic therapy. Patients with eosinophilic esophagitis, as with asthma, often have elevated serum markers of atopy, including IgE levels, peripheral eosinophil counts, and T-helper type 2-associated cytokines. A review of the literature shows that the true incidence of eosinophilic esophagitis remains poorly understood due to the difficulty of diagnosing this pathology, which has a mask of gastroesophageal reflux disease. Gastroesophageal reflux disease has been shown to influence asthma through microaspiration, airway hyperresponsiveness, and increased vagal tone. Understanding the relationship between gastroesophageal reflux and eosinophilic esophagitis is also being actively explored. Many works show the high efficacy of PPIs in the initial treatment of eosinophilic esophagitis and gastroesophageal reflux disease. The development of new clinical diagnostic criteria for eosinophilic esophagitis will improve the differential diagnosis of this disease and the improvement of therapeutic strategies for managing this pathology, especially in combination with asthma.
About the Authors
I. V. Zaikova-Khelimskaya
Far Eastern State Medical University
Russian Federation
Russian Federation
M. Yu. Bank
Far Eastern State Medical University
Russian Federation
Russian Federation
A. A. Khelimskiy
MIREA - Russian Technological University
Russian Federation
Russian Federation
References
1. Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Clinical Guidelines of the Russian Gastroenterological Association on the Diagnostics and Treatment of Eosinophilic Esophagitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(6):84-98. (In Russ.) doi: 10.22416/1382-4376-2018-28-6-84-98.@@ Ивашкин В.Т., Маев И.В., Трухманов А.С., Лапина Т.Л., Андреев Д.Н., Баранская Е.К., Тертычный А.С., Пирогов С.С., Шептулин А.А., Абдулганиева Д.И., Дичева Д.Т., Заборовский А.В., Ивашкина Н.Ю., Корочанская Н.В., Параскевова А.В. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эозинофильного эзофагита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(6):84-98. doi: 10.22416/1382-4376-2018-28-6-84-98.
2. Furuta G.T., Katzka D.A. Eosinophilic Esophagitis. N Engl J Med. 2015 Oct 22;373(17):1640-8. doi: 10.1056/NEJMra1502863.
3. Dellon E.S., Hirano I. Epidemiology and Natural History of Eosinophilic Esophagitis. Gastroenterology. 2018 Jan;154(2):319-332.e3. doi: 10.1053/j.gastro.2017.06.067.
4. Roy-Ghanta S., Larosa D.F., Katzka D.A. Atopic characteristics of adult patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2008 May;6(5):531-5. doi: 10.1016/j.cgh.2007.12.045.
5. Simon D., Cianferoni A., Spergel J.M. et al. Eosinophilic esophagitis is characterized by a non-IgE-mediated food hypersensitivity. Allergy. 2016 May;71(5):611-20. doi: 10.1111/all.12846.
6. Shaheen N.J., Mukkada V., Eichinger C.S., Schofield H., Todorova L., Falk G.W. Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course. Dis Esophagus. 2018 Aug 1;31(8):doy015. doi: 10.1093/dote/doy015.
7. Alexander E.S., Martin L.J., Collins M.H. et al. Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis. J Allergy Clin Immunol. 2014 Nov;134(5):1084-1092.e1. doi: 10.1016/j.jaci.2014.07.021.
8. Warners M., de Rooij W.E., Van Rhijn B.D., Verheij J., Smout A.J., Bredenoord A.J. Large Increase in Incidence of Eosinophilc Esophagitis Over the Last 20 Years in the Netherlands: Results from a Nationwide Pathology Database. Gastroenterology. 2017;152:S862-S863. AGA Abstracts: Tu1104. doi: 10.1016/S0016-5085(17)32964-5.
9. Arias Á., Pérez-Martínez I., Tenías J.M., Lucendo A.J. Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2016 Jan;43(1):3-15. doi: 10.1111/apt.13441.
10. Kaibysheva V.O., Kashin S.V., Mikhaleva L.M. et al. Eosinophilic esophagitis: current view on the problem and own clinical observations.Russian Journal of Evidence-based Gastroenterology=Dokazatel’naya gastroenterologiya. 2019;8(1):58-83. (In Russ.) doi: 10.17116/dokgastro2019801158.@@ Кайбышева В.О., Кашин С.В., Михалева Л.М., Видяева Н.С., Куваев Р.О., Галкова З.В., Ильчишина Т.А., Печникова В.В., Никонов Е.Л., Шаповальянц С.Г. Эозинофильный эзофагит: современный взгляд на проблему и собственные клинические наблюдения. Доказательная гастроэнтерология. 2019;8(1):58-83. doi: 10.17116/dokgastro2019801158.
11. Giriens B., Yan P., Safroneeva E. et al. Escalating incidence of eosinophilic esophagitis in Canton of Vaud, Switzerland, 1993-2013: a population-based study. Allergy. 2015 Dec;70(12):1633-9. doi: 10.1111/all.12733.
12. Prasad G.A., Alexander J.A., Schleck C.D., Zinsmeister A.R., Smyrk T.C., Elias R.M., Locke G.R. 3rd, Talley N.J. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1055-61. doi: 10.1016/j.cgh.2009.06.023.
13. Ntuli Y., Bough I., Wilson M. Recognising eosinophilic oesophagitis as a cause of food bolus obstruction. Frontline Gastroenterol. 2020 Jan;11(1):11-15. doi: 10.1136/flgastro-2019-101176.
14. García-Compeán D., González González J.A., Marrufo García C.A. et al. Prevalence of eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease symptoms: A prospective study. Dig Liver Dis. 2011 Mar;43(3):204-8. doi: 10.1016/j.dld.2010.08.002.
15. Achem S.R., Almansa C., Krishna M., Heckman M.G., Wolfsen H.C., Talley N.J., DeVault K.R. Oesophageal eosinophilic infiltration in patients with noncardiac chest pain. Aliment Pharmacol Ther. 2011 Jun;33(11):1194-201. doi: 10.1111/j.1365-2036.2011.04652.x.
16. Navarro P., Arias Á., Arias-González L., Laserna-Mendieta E.J., Ruiz-Ponce M., Lucendo A.J. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2019 May;49(9):1116-1125. doi: 10.1111/apt.15231.
17. Cook D., Zala A., Bollipo S., Potter M.D.E., Walker M.M., Talley N.J. Oesophageal food bolus obstruction and eosinophilic oesophagitis.Intern Med J. 2019 Aug;49(8):1032-1034. doi: 10.1111/imj.14389.
18. Chehade M., Jones S.M., Pesek R.D. et al. Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research. J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1534-1544.e5. doi: 10.1016/j.jaip.2018.05.038.
19. Furuta G.T., Liacouras C.A., Collins M.H., Gupta S.K., Justinich C., Putnam P.E., Bonis P., Hassall E., Straumann A., Rothenberg M.E.; First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007 Oct;133(4):1342-63. doi: 10.1053/j.gastro.2007.08.017.
20. Moawad F.J., Dellon E.S., Achem S.R. et al. Effects of Race and Sex on Features of Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2016 Jan;14(1):23-30. doi: 10.1016/j.cgh.2015.08.034.
21. Schoepfer A.M., Straumann A., Panczak R., Coslovsky M. et al.; International Eosinophilic Esophagitis Activity Index Study Group. Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis. Gastroenterology. 2014 Dec;147(6):1255-66.e21. doi: 10.1053/j.gastro.2014.08.028.
22. Dellon E.S., Speck O., Woodward K., Covey S., Rusin S., Shaheen N.J., Woosley J.T. Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol. 2015 Mar;28(3):383-90. doi: 10.1038/modpathol.2014.110.
23. Virchow J.C. Eosinophilic esophagitis: asthma of the esophagus? Dig Dis. 2014;32(1-2):54-60. doi: 10.1159/000357010.
24. Sherrill J.D., Gao P.S., Stucke E.M. et al. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol. 2010 Jul;126(1):160-5.e3. doi: 10.1016/j.jaci.2010.04.037.
25. Cohen M.C., Rao P., Thomson M., Al-Adnani M. Eosinophils in the oesophageal mucosa: clinical, pathological and epidemiological relevance in children: a cohort study. BMJ Open. 2012 Jan 12;2(1):e000493. doi: 10.1136/bmjopen-2011-000493.
26. Niranjan R., Rayapudi M., Mishra A., Dutt P., Dynda S., Mishra A. Pathogenesis of allergen-induced eosinophilic esophagitis is independent of interleukin (IL)-13. Immunol Cell Biol. 2013 Jul;91(6):408-15. doi: 10.1038/icb.2013.21.
27. Lockett G.A., Holloway J.W. Genome-wide association studies in asthma; perhaps, the end of the beginning. Curr Opin Allergy Clin Immunol. 2013 Oct;13(5):463-9. doi: 10.1097/ACI.0b013e328364ea5f.
28. Hines B.T., Rank M.A., Wright B.L., Marks L.A. et al. Minimally invasive biomarker studies in eosinophilic esophagitis: A systematic review. Ann Allergy Asthma Immunol. 2018; 121(2):218-28. doi:10.1016/j.anai.2018.05.005.
29. Straumann A., Conus S., Grzonka P. et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010 Jan;59(1):21-30. doi: 10.1136/gut.2009.178558.
30. Dougherty R.H., Sidhu S.S., Raman K., Solon M., Solberg O.D., Caughey G.H., Woodruff P.G., Fahy J.V. Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. J Allergy Clin Immunol. 2010 May;125(5):1046-1053.e8. doi: 10.1016/j.jaci.2010.03.003.
31. Rothenberg M.E. Molecular, genetic, and cellular bases for treating eosinophilic esophagitis. Gastroenterology. 2015 May;148(6):1143-57. doi: 10.1053/j.gastro.2015.02.002.
32. Salem S.B., Kushner Y., Marcus V., Mayrand S., Fallone C.A., Barkun A.N. The potential impact of contemporary developments in the management of patients with gastroesophageal reflux disease undergoing an initial gastroscopy. Can J Gastroenterol. 2009 Feb;23(2):99-104. doi: 10.1155/2009/859271.
33. Camacho C., Velazquez V., Vicente M., Sierra C., Zayas, P. Association between Eosinophilic Esophagitis and Asthma. Journal of Allergy and Clinical Immunology. 2017:139(2): AB52. Abstracts: 165. doi: 10.1016/j.jaci.2016.12.122
34. González-Cervera J., Arias Á., Redondo-González O., Cano-Mollinedo M.M., Terreehorst I., Lucendo A.J. Association between atopic manifestations and eosinophilic esophagitis: A systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017 May;118(5):582-590.e2. doi: 10.1016/j.anai.2017.02.006.
35. Rajan J., Newbury R.O., Anilkumar A., Dohil R., Broide D.H., Aceves S.S. Long-term assessment of esophageal remodeling in patients with pediatric eosinophilic esophagitis treated with topical corticosteroids. J Allergy Clin Immunol. 2016 Jan;137(1):147-156.e8. doi: 10.1016/j.jaci.2015.05.045.
36. Hiremath G., Correa H., Acra S., Dellon E.S. Correlation of endoscopic signs and mucosal alterations in children with eosinophilic esophagitis. Gastrointest Endosc. 2020 Apr;91(4):785-794.e1. doi: 10.1016/j.gie.2019.11.031.
37. Ravi K., Talley N.J., Smyrk T.C., Katzka D.A., Kryzer L., Romero Y., Arora A.S., Alexander J.A. Low grade esophageal eosinophilia in adults: an unrecognized part of the spectrum of eosinophilic esophagitis? Dig Dis Sci. 2011 Jul;56(7):1981-6. doi: 10.1007/s10620-011-1594-1.
38. Savarino E.V., Tolone S., Bartolo O. et al. The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitor-responsive oesophageal eosinophilia is a GERD-related phenomenon. Aliment Pharmacol Ther. 2016 Sep;44(5):522-30. doi: 10.1111/apt.13718.
39. Souza R.F., Huo X., Mittal V. et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009 Nov;137(5):1776-84. doi: 10.1053/j.gastro.2009.07.055.
40. Ivashkin V.T., Baranskaya E.K., Kaibysheva V.O., Trukhmanov A.S., Sheptulin A.A. [Clinical guidelines for the diagnosis and treatment of eosinophilic esophagitis]. Moscow. 2013. (In Russ.)@@ Ивашкин В.Т., Баранская Е.К., Кайбышева В.О., Трухманов А.С., Шептулин А.А. Клинические рекомендации по диагностике и лечению эозинофильного эзофагита. М., 2013.
41. Lucendo A.J., Friginal-Ruiz A.B., Rodríguez B. Boerhaave’s syndrome as the primary manifestation of adult eosinophilic esophagitis. Two case reports and a review of the literature. Dis Esophagus. 2011 Feb;24(2):E11-5. doi: 10.1111/j.1442-2050.2010.01167.x.
42. Kim H.P., Vance R.B., Shaheen N.J., Dellon E.S. The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Sep;10(9):988-96.e5. doi: 10.1016/j.cgh.2012.04.019.
43. O’Shea K.M., Aceves S.S., Dellon E.S., Gupta S.K., Spergel J.M., Furuta G.T., Rothenberg M.E. Pathophysiology of Eosinophilic Esophagitis. Gastroenterology. 2018 Jan;154(2):333-345. doi: 10.1053/j.gastro.2017.06.065.
44. Cheng E., Souza R.F., Spechler S.J. Tissue remodeling in eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol. 2012 Dec 1;303(11):G1175-87. doi: 10.1152/ajpgi.00313.2012.
45. Bussmann C., Schoepfer A.M., Safroneeva E., Haas N., Godat S., Sempoux C., Simon H.U., Straumann A.Comparison of different biopsy forceps models for tissue sampling in eosinophilic esophagitis. Endoscopy. 2016 Dec;48(12):1069-1075. doi: 10.1055/s-0042-117274.
46. Laserna-Mendieta E.J., Casabona S., Savarino E., Perelló A., Pérez-Martínez I., Guagnozzi D., Barrio J., Guardiola A., Asensio T., de la Riva S., Ruiz-Ponce M., Rodríguez-Oballe J.A., Santander C., Arias Á., Lucendo A.J.; EUREOS EoE CONNECT research group. Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice. Clin Gastroenterol Hepatol. 2020 Dec;18(13):2903-2911.e4. doi: 10.1016/j.cgh.2020.01.024.
47. Sá C.C., Kishi H.S., Silva-Werneck A.L., Moraes-Filho J.P., Eisig J.N., Barbuti R.C., Hashimoto C.L., Navarro-Rodriguez T. Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor. Clinics (Sao Paulo). 2011;66(4):557-61. doi: 10.1590/s1807-59322011000400006.
48. Gómez-Torrijos E., García-Rodríguez R., Castro-Jiménez A., Rodríguez-Sanchez J., Méndez Díaz Y., Molina-Infante J. The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther. 2016 Feb;43(4):534-40. doi: 10.1111/apt.13496.
49. Alexander J.A., Jung K.W., Arora A.S. et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):742-749.e1. doi: 10.1016/j.cgh.2012.03.018.
50. Hines B.T., Rank M.A., Wright B.L., Marks L.A. et al. Minimally invasive biomarker studies in eosinophilic esophagitis: A systematic review. Ann Allergy Asthma Immunol. 2018;121(2):218-28. doi:10.1016/j.anai.2018.05.005
51. Dhar A., Haboubi H.N., Attwood S.E. et al. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut. 2022 Aug;71(8):1459-1487. doi: 10.1136/gutjnl-2022-327326.
52. Hirano I., Chan E.S., Rank M.A., Sharaf R.N., Stollman N.H., Stukus D.R., Wang K., Greenhawt M., Falck-Ytter Y.T.; AGA Institute Clinical Guidelines Committee; Joint Task Force on Allergy-Immunology Practice Parameters. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology. 2020 May;158(6):1776-1786. doi: 10.1053/j.gastro.2020.02.038.
53. Ma C., Schoepfer A.M., Safroneeva E.; COREOS Collaborators; COREOS Collaborators. Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus. Gastroenterology. 2021 Sep;161(3):748-755. doi: 10.1053/j.gastro.2021.04.080.
54. Moawad F.J., Veerappan G.R., Dias J.A., Baker T.P., Maydonovitch C.L., Wong R.K. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol. 2013 Mar;108(3):366-72. doi: 10.1038/ajg.2012.443.
55. Cianferoni A., Spergel J.M., Muir A. Recent advances in the pathological understanding of eosinophilic esophagitis. Expert Rev Gastroenterol Hepatol. 2015;9(12):1501-10. doi.org/10.1586/17474124.2015.1094372.
56. Vanstapel A., Vanuytsel T., De Hertogh G. Eosinophilic peak counts in eosinophilic esophagitis: a retrospective study. Acta Gastroenterol Belg. 2019 Apr-Jun;82(2):243-250. PMID: 31314183.
57. Collins M.H., Martin L.J., Alexander E.S. et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017 Feb 1;30(3):1-8. doi: 10.1111/dote.12470.
58. Collins MH, Martin LJ, Wen T, Abonia JP, Putnam PE, Mukkada VA, Rothenberg ME. Eosinophilic Esophagitis Histology Remission Score: Significant Relations to Measures of Disease Activity and Symptoms. J Pediatr Gastroenterol Nutr. 2020 May;70(5):598-603. doi: 10.1097/MPG.0000000000002637.
59. Saffari H., Peterson K.A., Fang J.C. et al. Patchy eosinophil distributions in an esophagectomy specimen from a patient with eosinophilic esophagitis: Implications for endoscopic biopsy. J Allergy Clin Immunol. 2012;130:798-800. doi:10.1016/j.jaci.2012.03.009.
60. Dunn J.L.M., Shoda T., Caldwell J.M. et al.; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort. J Allergy Clin Immunol. 2020 Jun;145(6):1629-1640.e4. doi: 10.1016/j.jaci.2020.01.051.
61. Hirano I., Collins M.H., Assouline-Dayan Y. et al.; HEROES Study Group. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology. 2019 Feb;156(3):592-603.e10. doi: 10.1053/j.gastro.2018.10.051.
62. Shoda T., Wen T., Aceves S.S., et al.; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. Lancet Gastroenterol Hepatol. 2018 Jul;3(7):477-488. doi: 10.1016/S2468-1253(18)30096-7.
63. Kottyan L.C., Rothenberg M.E. Genetics of eosinophilic esophagitis. Mucosal Immunol. 2017 May;10(3):580-588. doi: 10.1038/mi.2017.4.
64. Murali A.R., Gupta A., Attar B.M. et al. Topical steroids in eosinophilic esophagitis: systematic review and metaanalysis of placebo controlled randomized clinical trials. J Gastroenterol Hepatol. 2015;31:1111-9.
65. Clayton F., Fang J.C., Gleich G.J. et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014 Sep;147(3):602-9. doi: 10.1053/j.gastro.2014.05.036.
66. Zukerberg L., Mahadevan K., Selig M., Deshpande V. Oesophageal intrasquamous IgG4 deposits: an adjunctive marker to distinguish eosinophilic oesophagitis from reflux oesophagitis. Histopathology. 2016 Jun;68(7):968-76. doi: 10.1111/his.12892.
67. Rosenberg C.E., Mingler M.K., Caldwell J.M., Collins M.H., Fulkerson P.C., Morris D.W., Mukkada V.A., Putnam P.E., Shoda T., Wen T., Rothenberg M.E. Esophageal IgG4 levels correlate with histopathologic and transcriptomic features in eosinophilic esophagitis. Allergy. 2018 Sep;73(9):1892-1901. doi: 10.1111/all.13486.
68. Mohammad N., Avinashi V., Chan E., Vallance B.A., Portales-Casamar E., Bush J.W. Pediatric Eosinophilic Esophagitis Is Associated With Increased Lamina Propria Immunoglobulin G4-Positive Plasma Cells. J Pediatr Gastroenterol Nutr. 2018 Aug;67(2):204-209. doi: 10.1097/MPG.0000000000001949.
69. Dellon E.S., Gonsalves N., Abonia J.P. et al.International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. Clin Gastroenterol Hepatol. 2022 Nov;20(11):2474-2484.e3. doi: 10.1016/j.cgh.2022.02.017.
70. Spergel B.L., Ruffner M.A., Godwin B.C. et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022 May;128(5):589-593. doi: 10.1016/j.anai.2022.01.019.
71. Dellon E.S., Rothenberg M.E., Collins M.H. et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022 Dec 22;387(25):2317-2330. doi: 10.1056/NEJMoa2205982.
72. Dixit C., Thatayatikom A., Pappa H., Knutsen A.P. Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome. J Allergy Clin Immunol Pract. 2021 Nov;9(11):4167-4169. doi: 10.1016/j.jaip.2021.06.049.
73. Aceves S.S., Dellon E.S., Greenhawt M., Hirano I., Liacouras C.A., Spergel J.M. Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick. Ann Allergy Asthma Immunol. 2023 Mar;130(3):371-378. doi: 10.1016/j.anai.2022.12.014.
74. Dellon E.S., Spergel J.M. Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27. doi: 10.1016/j.anai.2022.06.015.
75. Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE). Available at: https://clinicaltrials.gov/ct2/show/NCT03633617. Access 05.09.2023.
76. Agache I., Akdis C.A., Akdis M., Canonica G.W. et al. EAACI Biologicals Guidelines-Recommendations for severe asthma. Allergy. 2021 Jan;76(1):14-44. doi: 10.1111/all.14425.
77. Fokkens W.J., Viskens A.S., Backer V. et al. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. 2023 Jun 1;61(3):194-202. doi: 10.4193/Rhin22.489.
78. Bacharier L.B., Maspero J.F., Katelaris C.H. et al.; Liberty Asthma VOYAGE Investigators. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. N Engl J Med. 2021 Dec 9;385(24):2230-2240. doi: 10.1056/NEJMoa2106567.
79. Benzecry, V.; Pravettoni, V.; Segatto, G.; Marzano, A.; Ferrucci, S. Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab. J. Investig. Allergol. Clin. Immunol. 2021, 31, 261-263. doi: 10.18176/jiaci.0614.
80. Kurbacheva3 O.M., Dyneva M.E., Ilina N.I. Dupilumab: basic aspects and applications to T2-mediated diseases. Meditsinskiy sovet = Medical Council. 2021;(16):186-196. (In Russ.) doi: 10.21518/2079-701X-2021-16-186-196.@@ Курбачева О.М., Дынева М.Е., Ильина Н.И. Дупилумаб: основные аспекты применения при T2-опосредованных заболеваниях. Медицинский совет. 2021;(16):186-196. doi: 10.21518/2079-701X-2021-16-186-196.
Review
For citations:
Zaikova-Khelimskaya I.V., Bank M.Yu., Khelimskiy A.A. Eosinophilic esophagitis and comorbid pathology: current state of the problem. Experimental and Clinical Gastroenterology. 2023;(11):138-145. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-219-11-138-145
Views:
186
Email this article 